Latest news

In Vitro Immune Cell-Mediated Killing

05 / 31 / 2017

Initiation of an anti-tumor immune response and further cancer cell elimination is a key step in cancer immunosurveillance. One of the current promising challenges in cancer immunotherapy is the potentiation of the specific attack of tumor cells by the immune system. Interestingly, in vitro immune cell killing is recognized as perhaps the most relevant functional measure to evaluate the ability of a candidate compound to promote such an effector function of immune cells.

Orthotopic Mouse Model Of Glioblastoma

02 / 14 / 2017

Glioblastoma (GBM) is the most aggressive primary brain tumor. Despite multimodal treatment strategies with surgery, radiation therapy and chemotherapy, the prognosis of GBM patients remains dismal. GBM are characterized by a high immune cells infiltration including myeloid derived suppressor cells (MDSCs), microglia or regulatory T cells (Tregs), all of them contributing to the creation of an immunosuppressive micro-environment. While manipulating the immune system to restore its anti-tumor activity have shown efficacy in many cancers, immunotherapy figures as an attractive therapeutic option for glioblastoma and several clinical trials are currently ongoing.

New Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

09 / 13 / 2016

After a full session in September, the next explicyte shuttle – anti-PD1 / anti-PDL1 syngeneic mouse models – is scheduled for the 25th of October.

The explicyte shuttle is a standardized study protocol in which you can include experimental groups in an already programmed study. Explicyte will cover the costs of the vehicle control group + the standard reference and sponsor will only cover its experimental groups.

In Vitro Immune Cell Killing Of Tumor Cells

07 / 12 / 2016

Cancer immunoediting is a dynamic process which consists in three phases including elimination, equilibrium and tumor immune escape. During the elimination step there is an engagement of effector cells such as natural killer or T cells which initiate tumor cell death – an event defective in case of tumor progression. Such key mechanism thus warrants investigation to optimize immune cell mediated killing of tumor cell. To this aim, we developed immune / tumor cells co-culture on a 96-well throughput platform to evaluate the capacity of candidate compounds to promote immune cell dependent tumor cell death alone and/or in combination with immune checkpoint inhibitors.

Take Part Of The Next Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

06 / 29 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-PD1 / anti-PD-L1 immunotherapy and/or evaluation of its ability to potentiate PD1/PD-L1 blockade mostly relies on immunocompetent mouse models in which the response to PD1/PD-L1 blockade has been already validated (see our recent news).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-PD1 and/or anti-PDL1 treated groups and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-PD1 and/or anti-PDL1 mAbs).

The next explicyte shuttle is scheduled for the 19th of September!

PD1 / PDL1 Blockade In Mouse Tumor Syngeneic Models

06 / 02 / 2016

Combinatory approaches in immuno-oncology with immune checkpoint inhibitors including anti-PD1 / PDL1 or anti-CTLA4 therapeutic antibodies is an active field of investigation. In order to evaluate potential synergistic effect of novel chemotherapeutic agents, immunostimulatory compounds, etc., we characterized the clinical response to anti-PD1 and anti-PDL1 in immunocompetent animal models. Ancillary studies including FACS analysis, RT-qPCR can provide support to delineate mechanism of actions of a drug candidate and can also support the identification of novel predictive biomarkers.